GleamWall
中文EN

CTXR Citius Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1506251 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-11.1%
TTM EPS YoY64.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-70.3%
ROA-34.3%
ROIC (approx.)-89.3%
Asset turnover—

Leverage & solvency

Liabilities / assets46.6%
Debt / equity0.00x
Current ratio0.84x
Interest coverage-127.24x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-8.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-09-30FY2024*2024-09-30
Income statement
Revenue——
R&D expense$9.16M$11.91M
SG&A expense$18.53M$18.25M
Operating income-$38.53M-$42.00M
Interest expense$267,782—
Pretax income-$38.68M-$38.85M
Income tax$1.06M$576,000
Net income-$37.43M-$39.14M
EBITDA—-$41.99M
EPS (basic)-3.38-5.97
EPS (diluted)-3.38-5.97
Weighted avg. shares (diluted)11.07M6.73M
Balance sheet
Cash & equivalents$4.25M$3.25M
Inventory$22.29M$8.27M
Current assets$27.93M$14.22M
Goodwill$9.35M$9.35M
Total assets$130.94M$116.65M
Current liabilities$44.91M$35.81M
Total liabilities$53.41M$42.55M
Shareholders' equity$67.55M$70.08M
Shares outstanding18.07M7.25M
Cash flow statement
Operating cash flow-$26.55M-$28.20M
Investing cash flow-$5.75M-$5.00M
Financing cash flow$33.30M$9.97M
Depreciation & amortization—$1,432
Stock-based compensation$10.84M$11.84M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.